11 research outputs found
Automated low flow ascites (ALFA) pump effectively reduces the number of large volume paracentesis - data from a real world cohort
Immune cell response in progressing liver cirrhosis is dominated by neutrophil granulocytes
Body fat composition determines outcomes before and after liver transplantation in patients with cirrhosis
Cachexia occurs in late stages of liver cirrhosis, and a low-fat
mass is potentially
associated with poor outcome. This study compared different computed
tomography (CT)âderived
fat parameters with respect to its prognostic impact
on the development of complications and death before and after liver
transplantation. Between 2001 and 2014, 612 patients with liver cirrhosis
without hepatocellular carcinoma listed for liver transplantation met the inclusion
criteria, including abdominal CT scan (±200 days to listing). A total
of 109 patients without cirrhosis served as controls. The subcutaneous fat
index (SCFI), the paraspinal muscle fat index, and the visceral fat index were
assessed at L3/L4 level and normalized to the height (cm2/m2). Data were collected
and analyzed retrospectively. Low SCFI was associated with a higher
rate of ascites and increased C-reactive
protein levels (p < 0.001). In addition,
multivariate Cox regression analysis adjusting for sex, age, body mass index
(BMI), and Model for End-Stage
Liver Disease showed that decreasing SCFI
was also associated with an increased risk of cirrhosis-related
complications
(p = 0.003) and death on the transplant wait list (p = 0.013). Increased paraspinal
and visceral fat were not only positively correlated with creatinine
levels (p < 0.001), BMI, and metabolic comorbidities (all p < 0.001) before
transplantation, but also predictive for 1-year
mortality after transplantation.
Conclusion: The distribution of body fat is a major determinant for complications
and outcome in cirrhosis before and after liver transplantation
Body fat composition determines outcomes before and after liver transplantation in patients with cirrhosis
Cachexia occurs in late stages of liver cirrhosis, and a low-fat
mass is potentially
associated with poor outcome. This study compared different computed
tomography (CT)âderived
fat parameters with respect to its prognostic impact
on the development of complications and death before and after liver
transplantation. Between 2001 and 2014, 612 patients with liver cirrhosis
without hepatocellular carcinoma listed for liver transplantation met the inclusion
criteria, including abdominal CT scan (±200 days to listing). A total
of 109 patients without cirrhosis served as controls. The subcutaneous fat
index (SCFI), the paraspinal muscle fat index, and the visceral fat index were
assessed at L3/L4 level and normalized to the height (cm2/m2). Data were collected
and analyzed retrospectively. Low SCFI was associated with a higher
rate of ascites and increased C-reactive
protein levels (p < 0.001). In addition,
multivariate Cox regression analysis adjusting for sex, age, body mass index
(BMI), and Model for End-Stage
Liver Disease showed that decreasing SCFI
was also associated with an increased risk of cirrhosis-related
complications
(p = 0.003) and death on the transplant wait list (p = 0.013). Increased paraspinal
and visceral fat were not only positively correlated with creatinine
levels (p < 0.001), BMI, and metabolic comorbidities (all p < 0.001) before
transplantation, but also predictive for 1-year
mortality after transplantation.
Conclusion: The distribution of body fat is a major determinant for complications
and outcome in cirrhosis before and after liver transplantation
Body fat composition determines outcomes before and after liver transplantation in patients with cirrhosis
Abstract Cachexia occurs in late stages of liver cirrhosis, and a lowâfat mass is potentially associated with poor outcome. This study compared different computed tomography (CT)âderived fat parameters with respect to its prognostic impact on the development of complications and death before and after liver transplantation. Between 2001 and 2014, 612 patients with liver cirrhosis without hepatocellular carcinoma listed for liver transplantation met the inclusion criteria, including abdominal CT scan (±200 days to listing). A total of 109 patients without cirrhosis served as controls. The subcutaneous fat index (SCFI), the paraspinal muscle fat index, and the visceral fat index were assessed at L3/L4 level and normalized to the height (cm2/m2). Data were collected and analyzed retrospectively. Low SCFI was associated with a higher rate of ascites and increased Câreactive protein levels (p < 0.001). In addition, multivariate Cox regression analysis adjusting for sex, age, body mass index (BMI), and Model for EndâStage Liver Disease showed that decreasing SCFI was also associated with an increased risk of cirrhosisârelated complications (p = 0.003) and death on the transplant wait list (p = 0.013). Increased paraspinal and visceral fat were not only positively correlated with creatinine levels (p < 0.001), BMI, and metabolic comorbidities (all p < 0.001) before transplantation, but also predictive for 1âyear mortality after transplantation. Conclusion: The distribution of body fat is a major determinant for complications and outcome in cirrhosis before and after liver transplantation
Tacrolimus and Mycophenolate Mofetil as Second-Line Therapies for Pediatric Patients with Autoimmune Hepatitis
Background: We studied the efficacy and safety of mycophenolate mofetil (MMF) and tacrolimus as second-line therapy in pediatric patients with autoimmune hepatitis (AIH) who were intolerant or non-responders to standard therapy (corticosteroid and azathioprine). Patients and Methods: We performed a retrospective study of data from 13 centers in Europe, USA, and Canada. Thirty-eight patients (< 18\ua0years old) who received second-line therapy (18 MMF and 20 tacrolimus), for a median of 72\ua0months (range 8\u2013182) were evaluated. Patients were categorized into two groups: Group 1 (n = 17) were intolerant to corticosteroid or azathioprine, and group 2 (n = 21) were non-responders to standard therapy. Results: Overall complete response rates were similar in patients treated with MMF and tacrolimus (55.6 vs. 65%, p = 0.552). In group 1, MMF and tacrolimus maintained a biochemical remission in 88.9 and 87.5% of patients, respectively (p = 0.929). More patients in group 2 given tacrolimus compared to MMF had a complete response, but the difference was not statistically significant (50.0 vs. 22.2%, p = 0.195). Biochemical remission was achieved in 71.1% (27/38) of patients by tacrolimus and/or MMF. Decompensated cirrhosis was more commonly seen in MMF and/or tacrolimus non-responders than in responders (45.5 vs. 7.4%, p = 0.006). Five patients who received second-line therapy (2 MMF and 3 tacrolimus) developed side effects that led to therapy withdrawal. Conclusions: Long-term therapy with MMF or tacrolimus was generally well tolerated by pediatric patients with AIH. Both MMF and tacrolimus had excellent efficacy in patients intolerant to corticosteroid or azathioprine. Tacrolimus might be more effective than MMF in patients failing previous therapy
Granulocyte-colony stimulating factor (G-CSF) to treat acute-on- chronic liver failure: A multicenter randomized trial (GRAFT study)
Background & Aims: Based on positive results from small single center studies, granulocyte-colony stimulating factor (G-CSF) is being widely used for the treatment of patients with acute-on chronic liver failure (ACLF). Herein, we aimed to evaluate the safety and efficacy of G-CSF in patients with ACLF. Methods: In this multicenter, prospective, controlled, open-label phase II study, 176 patients with ACLF (EASL-CLIF criteria) were randomized to receive G-CSF (5 mu g/kg daily for the first 5 days and every third day thereafter until day 26) plus standard medical therapy (SMT) (n = 88) or SMT alone. The primary effi- cacy endpoint was 90-day transplant-free survival analyzed by Cox regression modeling. The key secondary endpoints were overall and transplant-free survival after 360 days, the development of ACLF-related complications, and the course of liver function scores during the entire observation period. Results: Patients treated with G-CSF had a 90-day transplant free survival rate of 34.1% compared to 37.5% in the SMT group (hazard ratio [HR] 1.05; 95% CI 0.711-1.551; p = 0.805). Transplant-free and overall survival at 360 days did not differ between the 2 arms (HR 0.998; 95% CI 0.697-1.430; p = 0.992 and HR 1.058; 95% CI 0.727-1.548; p = 0.768, respectively). G-CSF did not improve liver function scores, the occurrence of infections, or survival in subgroups of patients without infections, with alcohol-related ACLF, or with ACLF defined by the APASL criteria. Sixty-one serious adverse events were reported in the GCSF+SMT group and 57 were reported in the SMT group. In total, 7 drug-related serious adverse reactions occurred in the G-CSF group. The study was prematurely terminated due to futility after conditional power calculation. Conclusions: In contrast to previous findings, G-CSF had no significant beneficial effect on patients with ACLF in this multicenter controlled trial, which suggests that it should not be used as a standard treatment for ACLF. ClinicalTrials.gov number: NCT02669680 Lay summary: Granulocyte-colony stimulating factor was considered as a novel treatment for acute-on-chronic liver failure (ACLF). We performed the first randomized, multicenter, controlled phase II trial, which showed that G-CSF did not improve survival or other clinical endpoints in patients with ACLF. Therefore, G-CSF should not be used to treat liver disease outside clinical studies. (C) 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved